Publications
Selected publications
Porotto M, Greengard O, Poltoratskaia N, Horga M-A, Moscona A. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J Virol 75 (16): 7481-7488, 2001.
Porotto M, Murrell M, Greengard O, Moscona A. Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN): an HN mutation diminishing the rate of F activation and fusion. J Virol 77(6): 3647-3654, 2003.
Porotto M, Murrell M, Greengard O, Lawrence M, McKimm-Breschkin JL, Moscona A. Inhibition of parainfluenza type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites. J Virol 78 (24): 13911-13919, 2004.
Porotto M, Murrell M, Greengard O, Doctor L, Moscona A. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J Virol 79 (4): 2383-2392, 2005.
Porotto M, Fornabaio M, Greengard O, Murrell MT, Kellogg GE, Moscona A. Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site. J Virol 80 (3), 1204-1213, 2006. (Editor's Spotlight)
Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A. Inhibition of Hendra virus fusion. J Virol 80 (19), 9837-9839, 2006.
Porotto M, Fornabaio M, Kellogg GE, Moscona A. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. J Virol 81 (7): 3216-28, 2007.
Porotto M,* Carta P, Deng Y, Kellogg GE, Whitt M, Lu M, Mungall BA, Moscona, A. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J Virol 81 (19): 10567-74, 2007.
Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, Aljofan M, Whitt M, Glickman F, Moscona A. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol. 83(10):5148-55, 2009. (Editor's Spotlight)
Porotto M, Yokoyama CC, Orefice G, Kim HS, Aljofan M, Mungall BA, Moscona A. Kinetic dependence of paramyxovirus entry inhibition. J Virol. 83(13): 6947-6951, 2009.
Porotto M, Yokoyama C, Palermo LM, Mungall B, Aljofan M, Cortese R, Pessi A, Moscona A. Viral entry inhibitors targeted to the membrane site of action. J Virol. 84 (13): 6760-6768, 2010
Porotto M, Rockx B, Yokoyama CC, Talekar A, DeVito I, Palermo LM, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathogens 6 (10) October, 2010.
Porotto M, Yi F, Moscona A, LaVan DA. Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus. PLoS One. 2011 Mar 1;6(3):e16874.
Talekar A., Pessi P., Porotto M. Natural tissue infection mediated by Nipah envelope proteins: evaluating host target cells for antiviral assessment. J Virol. 2011 Aug;85(16):8422-6. Epub 2011 Jun 8.
Porotto M, Devito I, Palmer SG, Jurgens EM, Yee JL, Yokoyama CC, Pessi A, Moscona A. Spring-loaded model revisited: Paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein. J Virol. 2011 Dec;85(24):12867-80. Epub 2011 Oct 5.
Lee KK, Pessi P., Santoprete A., Talekar A., Moscona A, Porotto M. Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide: a new antiviral strategy for influenza virus. J Biol Chem. 2011 Dec 9;286(49):42141-9. Epub 2011 Oct 12.
Porotto M, Palmer SG, Palermo LM, Moscona A. Mechanism of Fusion Triggering by Human Parainfluenza Virus Type III: COMMUNICATION BETWEEN VIRAL GLYCOPROTEINS DURING ENTRY. J Biol Chem. 2012 Jan 2;287(1):778-93. Epub 2011 Nov 22.
Talekar A., SenGupta U., Moscona A., Glickman F., Briese T., Whitt M., Pessi P., Mathieu C., Horvat B., Porotto M. Rapid Development of Treatments and Screening systems for Emerging Viral Diseases. PLoS One. 2012;7(3):e30538. Epub 2012 Mar 2.
Porotto M , Salah Z., De Vito I., Talekar A., Palmer S.G., R., Wilson I.A., Moscona A and. The second receptor binding site of the globular head of the Newcastle disease virus (NDV) hemagglutinin-neuraminidase activates the stalk of multiple paramyxoviruses to trigger fusion. J Virol. 2012 Mar 21. [Epub ahead of print]
Pessi A, Langella A., Capitò E., Ghezzi S., Vicenzi E, Mathieu C., Poli G., Ketas T., Cortese R, Horvat B., Moscona A., and Porotto M. A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity In Vivo. PLoS One. In press.
